Project Description

BreakBio
Using Data Science And A.I. To Make Cancer Treatment More Personal

Date & Time:

February 26, 12:00 PM ET / 9:00 AM PT
Webinar: Details provided upon RSVP approval

About the Event:

When Silicon Valley entrepreneur Roy de Souza’s wife was diagnosed with metastatic Colorectal Cancer (mCRC), he was shocked to learn of the low survival rates. Especially since mCRC is the second most common cancer in women and third most common cancer in men worldwide.

So he founded BreakBio along with Sri Srikrishna and they assembled a team from Memorial Sloan Kettering Cancer Center, Harvard’s Dana Farber Cancer Institute, MIT and other leading institutions to develop a cure.

BreakBio is making a breakthrough in the treatment of mCRC with a three phased approach:
  • They map a patient’s individual genome and use AI to spot the difference between healthy cells and cancer cells.
  • They develop a personalized vaccine that stimulates the immune system to target those cancer cells more effectively, without attacking healthy cells.
  • They slow the growth of cancer so T-Cells kill faster than the cancer cells can reproduce.
Join Roy February 26, at 12:00 p.m. ET for a webinar to learn about the science behind their approach, the people who are making it happen, and the value created by getting a Breakthrough Designation from the FDA.

Share this Event

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.